These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Gene therapy for haemophilia. Murphy SL; High KA Br J Haematol; 2008 Mar; 140(5):479-87. PubMed ID: 18275425 [TBL] [Abstract][Full Text] [Related]
24. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Van Damme A; Chuah MK; Collen D; VandenDriessche T Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930 [TBL] [Abstract][Full Text] [Related]
25. Haemophilias A and B. Bolton-Maggs PH; Pasi KJ Lancet; 2003 May; 361(9371):1801-9. PubMed ID: 12781551 [TBL] [Abstract][Full Text] [Related]
26. Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia? Liras A Thromb Res; 2011 Jul; 128(1):8-13. PubMed ID: 21396685 [TBL] [Abstract][Full Text] [Related]
28. New high-technology products for the treatment of haemophilia. Pipe SW; Saint-Remy JM; Walsh CE Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373 [TBL] [Abstract][Full Text] [Related]
29. Emerging therapies for haemophilia - Global perspective. Mahlangu J; Cerquiera M; Srivastava A Haemophilia; 2018 May; 24 Suppl 6():15-21. PubMed ID: 29878661 [TBL] [Abstract][Full Text] [Related]
30. Recent progress in gene therapy for hemophilia. Chuah MK; Nair N; VandenDriessche T Hum Gene Ther; 2012 Jun; 23(6):557-65. PubMed ID: 22671033 [TBL] [Abstract][Full Text] [Related]
31. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Iorio A; Skinner MW; Clearfield E; Messner D; Pierce GF; Witkop M; Tunis S; Haemophilia; 2018 Jul; 24(4):e167-e172. PubMed ID: 29781145 [TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040 [TBL] [Abstract][Full Text] [Related]
33. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences. Chuah MK; Vandendriessche T Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006 [TBL] [Abstract][Full Text] [Related]
36. Gene therapy strategies for hemophilia: benefits versus risks. Petrus I; Chuah M; VandenDriessche T J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668 [TBL] [Abstract][Full Text] [Related]
37. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy. Youjin S; Jun Y Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215 [TBL] [Abstract][Full Text] [Related]
38. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096 [TBL] [Abstract][Full Text] [Related]
39. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373 [TBL] [Abstract][Full Text] [Related]
40. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. Monahan PE Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]